Oncology

Possible higher risk of recurrence in association with drinking seen for women with lower body mass index. For women with breast cancer with higher body mass index (BMI), alcohol drinking is associated with a lower risk of overall mortality, according to a study published online Aug. 9 in Cancer. Marilyn L. Kwan, Ph.D., from Kaiser...

Medically reviewed by Dr. Shani S. Saks, D.O. on August 2, 2023 A recent case report focused on the development of vitiligo in a 71-year-old African American male with a large-cell, poorly differentiated neuroendocrine tumor while undergoing treatment with atezolizumab.  In recent years, immune checkpoint inhibitors (ICIs) have revolutionized cancer treatment by enhancing the immune...

Medically reviewed by Dr. Shani S. Saks, D.O. on August 2, 2023 In a phase 3 trial, ciltacabtagene autoleucel caused a significantly lower risk of disease progression or death than standard care in lenalidomide-refractory multiple myeloma patients. The frequency of lenalidomide resistance early in multiple myeloma (MM) treatment is increasing, leading to a need for...

Medically reviewed by Dr. Shani S. Saks, D.O. on August 2, 2023 Patients in a phase 1–2 study who were treated with teclistamab demonstrated a high rate of durable and deep therapeutic response. The treatment was safe and effective. Most of the toxic effects that were associated with T-cell redirection were categorized as grade 1...

Medically reviewed by Dr. Shani S. Saks, D.O. on August 2, 2023 In a phase 1 study, talquetamab induced a substantial therapeutic response in patients suffering from multiple myeloma. The bispecific antibody was safe except for low-grade cytokine release syndrome, dysgeusia, and skin-related events. Malignant plasma cells in multiple myeloma express the G protein-coupled receptor,...

Medically reviewed by Dr. Shani S. Saks, D.O. on August 2, 2023 Ide-cel therapy significantly improved response and progression-free survival compared to standard regimens in triple-class-exposed relapsed and refractory multiple myeloma patients. Relapsed and refractory multiple myeloma (MM) patients with triple-class exposure display suboptimal responses to standard therapies, leading to poor survival outcomes. Idecabtagene vicleucel...

Medically reviewed by Dr. Shani S. Saks, D.O. on August 2, 2023 In this study of multiple myeloma, patients who experienced a complete response had longer survival periods and higher 5-year survival rates compared to non-complete response patients. The development of a unique prediction model based on transcriptome data allowed for the identification of individuals...

Medically reviewed by Dr. Samuel Sarmiento, M.D., MPH on August 23, 2023 This study found ixazomib to be an effective and feasible maintenance therapy for newly diagnosed multiple myeloma patients, regardless of age or frailty status. Elderly multiple myeloma (MM) patients have reduced survival and quality-of-life (QoL) compared to younger patients due to comorbidities, increased...

In this exclusive MD Newsline webcast Hematology-Oncology Specialists Dr. Mouhammed Kelta and Dr. Shaina Rozell discuss health disparities in Multiple Myeloma. View the webcast here.